PT3484862T - Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia - Google Patents
Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemiaInfo
- Publication number
- PT3484862T PT3484862T PT178315784T PT17831578T PT3484862T PT 3484862 T PT3484862 T PT 3484862T PT 178315784 T PT178315784 T PT 178315784T PT 17831578 T PT17831578 T PT 17831578T PT 3484862 T PT3484862 T PT 3484862T
- Authority
- PT
- Portugal
- Prior art keywords
- sympton
- hyperuricemia
- gout
- compositions
- treating
- Prior art date
Links
- 201000005569 Gout Diseases 0.000 title 1
- 201000001431 Hyperuricemia Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363473P | 2016-07-18 | 2016-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3484862T true PT3484862T (pt) | 2021-11-17 |
Family
ID=60992707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT178315784T PT3484862T (pt) | 2016-07-18 | 2017-07-12 | Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US10239854B2 (pt) |
| EP (2) | EP3484862B1 (pt) |
| JP (3) | JP2019524747A (pt) |
| KR (1) | KR102610573B1 (pt) |
| CN (3) | CN109790135B (pt) |
| AU (1) | AU2017298142B2 (pt) |
| CA (1) | CA3030821A1 (pt) |
| DK (1) | DK3484862T3 (pt) |
| EA (1) | EA201990333A1 (pt) |
| ES (2) | ES2964344T3 (pt) |
| IL (1) | IL264268B (pt) |
| PL (1) | PL3484862T3 (pt) |
| PT (1) | PT3484862T (pt) |
| SG (1) | SG11201900405XA (pt) |
| WO (1) | WO2018017368A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11166983B2 (en) | 2015-06-09 | 2021-11-09 | Lymphact—Lymphocyte Activation Technologies, S.A. | Methods for the production of TCRγδ+ T cells |
| PT3484862T (pt) | 2016-07-18 | 2021-11-17 | Arthrosi Therapeutics Inc | Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia |
| CA3121913A1 (en) * | 2018-12-06 | 2020-06-11 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| US20220023251A1 (en) * | 2018-12-06 | 2022-01-27 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing gout or hyperuricemia |
| BR112021022843A2 (pt) * | 2019-05-14 | 2022-03-03 | Arthrosi Therapeutics Inc | Composto para tratamento de gota ou hiperuricemia |
| BR112021024738A2 (pt) * | 2019-06-17 | 2022-05-03 | Fochon Pharmaceuticals Ltd | Derivados heterocíclicos e uso dos mesmos |
| KR20230024354A (ko) * | 2020-06-10 | 2023-02-20 | 아쓰로시 테라퓨틱스, 인크. | 만성 신장 질환을 치료 또는 예방하는 방법 |
| WO2022169974A1 (en) | 2021-02-05 | 2022-08-11 | Nexys Therapeutics, Inc. | Inhibitors of urat1 and pharmaceutical uses thereof |
| TW202330485A (zh) * | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | 用於治療或預防痛風或高尿酸血症之化合物的結晶形式 |
| TW202334103A (zh) * | 2021-12-30 | 2023-09-01 | 美商安索治療公司 | 用於治療痛風或高尿酸血症之化合物之製備 |
| WO2023149549A1 (ja) * | 2022-02-03 | 2023-08-10 | 国立大学法人富山大学 | 新規医薬組成物 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1023985A (en) | 1911-05-29 | 1912-04-23 | Louis Emile Beaulieu | Fish-plate bolt. |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
| AU1537292A (en) | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
| RU2120798C1 (ru) | 1991-11-22 | 1998-10-27 | Проктер энд Гэмбл Фармасьютикалз, Инк. | Твердая фармацевтическая композиция для перорального введения |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| KR100291362B1 (ko) | 1992-10-16 | 2001-09-17 | 니뽄 신야쿠 가부시키가이샤 | 왁스매트릭스의제법 |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| DE19624292A1 (de) * | 1996-06-18 | 1998-01-02 | Merckle Gmbh | Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| EP1767531A4 (en) * | 2004-06-10 | 2011-01-05 | Torii Pharmaceutical Co Ltd | MEDICINAL COMPOSITIONS CONTAINING 6-HYDROXYBENZBROMARONE OR SALTS THEREOF |
| US20080305169A1 (en) * | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
| CA2685344A1 (en) * | 2007-04-26 | 2008-11-06 | Auspex Pharmaceuticals, Inc. | Deuterium labelled ketamine |
| JP5325065B2 (ja) * | 2009-09-30 | 2013-10-23 | 株式会社富士薬品 | 新規フェノール誘導体 |
| GB2484298A (en) | 2010-10-05 | 2012-04-11 | Plexus Ocean Syst Ltd | Subsea wellhead with adjustable hanger forming an annular seal |
| US10005750B2 (en) | 2010-10-06 | 2018-06-26 | J-Pharma Co., Ltd. | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action |
| US20150031768A1 (en) | 2011-08-19 | 2015-01-29 | The Trustees Of Princeton University | C-halogen bond formation |
| US9962362B2 (en) | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| WO2014113407A2 (en) | 2013-01-16 | 2014-07-24 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting eya tyrosine phosphatase |
| CN105579037A (zh) * | 2013-05-31 | 2016-05-11 | 武田制药美国有限公司 | 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物 |
| WO2015134467A1 (en) * | 2014-03-05 | 2015-09-11 | The Trustees Of Princeton University | Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks |
| MX2017001103A (es) | 2014-07-31 | 2017-04-27 | Merck Patent Gmbh | Derivados de indolizina que son aplicables a enfermedades neurodegenerativas. |
| CN104311516B (zh) | 2014-09-16 | 2017-01-11 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型b及其制备方法 |
| CN104262305B (zh) | 2014-09-16 | 2016-06-08 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型a及其制备方法 |
| PT3484862T (pt) * | 2016-07-18 | 2021-11-17 | Arthrosi Therapeutics Inc | Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia |
| US20220023251A1 (en) | 2018-12-06 | 2022-01-27 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing gout or hyperuricemia |
| CA3121913A1 (en) | 2018-12-06 | 2020-06-11 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
-
2017
- 2017-07-12 PT PT178315784T patent/PT3484862T/pt unknown
- 2017-07-12 KR KR1020197004544A patent/KR102610573B1/ko active IP Right Grant
- 2017-07-12 ES ES21185425T patent/ES2964344T3/es active Active
- 2017-07-12 SG SG11201900405XA patent/SG11201900405XA/en unknown
- 2017-07-12 EP EP17831578.4A patent/EP3484862B1/en active Active
- 2017-07-12 DK DK17831578.4T patent/DK3484862T3/da active
- 2017-07-12 CN CN201780057295.8A patent/CN109790135B/zh active Active
- 2017-07-12 ES ES17831578T patent/ES2897968T3/es active Active
- 2017-07-12 JP JP2019502791A patent/JP2019524747A/ja active Pending
- 2017-07-12 WO PCT/US2017/041763 patent/WO2018017368A1/en unknown
- 2017-07-12 CA CA3030821A patent/CA3030821A1/en active Pending
- 2017-07-12 CN CN202110361823.7A patent/CN113214198B/zh active Active
- 2017-07-12 PL PL17831578T patent/PL3484862T3/pl unknown
- 2017-07-12 EA EA201990333A patent/EA201990333A1/ru unknown
- 2017-07-12 AU AU2017298142A patent/AU2017298142B2/en active Active
- 2017-07-12 IL IL264268A patent/IL264268B/en unknown
- 2017-07-12 EP EP21185425.2A patent/EP3957629B1/en active Active
- 2017-07-12 CN CN202211434030.4A patent/CN116332886A/zh active Pending
-
2018
- 2018-10-04 US US16/151,641 patent/US10239854B2/en active Active
-
2019
- 2019-02-05 US US16/268,367 patent/US10508093B2/en active Active
- 2019-11-14 US US16/684,046 patent/US11236058B2/en active Active
-
2020
- 2020-01-30 JP JP2020014109A patent/JP7418227B2/ja active Active
-
2021
- 2021-12-21 US US17/558,370 patent/US20220112171A1/en not_active Abandoned
-
2022
- 2022-08-04 US US17/817,440 patent/US20220396558A1/en not_active Abandoned
- 2022-09-12 JP JP2022144720A patent/JP2022188052A/ja active Pending
-
2023
- 2023-03-23 US US18/189,024 patent/US20230227419A1/en not_active Abandoned
- 2023-11-13 US US18/507,999 patent/US20240116888A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3484862T (pt) | Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia | |
| ZA201908154B (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| IL259795A (en) | Methods and compositions for treating diseases associated with serpinc1 | |
| IL262487B (en) | Compounds and methods for the treatment of neurological and cardiovascular conditions | |
| PT3348557T (pt) | Imidazo[1,2a]piridinas para o tratamento ou prevenção de hiperuricemia ou gota | |
| GB201710906D0 (en) | Compounds and methods for treating peripheral neuropathy | |
| HK1252692A1 (zh) | 治療或者預防蛋白質構象病的方法 | |
| IL283665A (en) | Methods for treating or preventing rheumatism or hyperuricemia | |
| IL287983A (en) | 15-hepe or a preparation containing 15-hepe for the treatment or prevention of fibrosis | |
| ZA201907975B (en) | Agent for preventing or treating tauopathy | |
| KR101675359B9 (ko) | 네오아가로올리고당을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물 | |
| EP3609522A4 (en) | METHODS AND COMPOUNDS FOR THE TREATMENT OF DIABETES | |
| HK1254232A1 (zh) | 用於治療胃潰瘍的方法和組合物 | |
| PL3489450T3 (pl) | Brama | |
| EP3823648C0 (en) | METHODS FOR THE TREATMENT OF DIABETES | |
| ZA201802090B (en) | A composition and method for treating substrates | |
| ZA201706716B (en) | A composition and method for treating substrates | |
| PL3695082T3 (pl) | Brama | |
| GB201706821D0 (en) | Compounds and methods for treating obesity | |
| GB201709559D0 (en) | Compounds for treating lupus |